Andrew B. Lichtenberg

Andrew represents technology companies, financial institutions, accounting firms and other businesses in class actions and other high-stakes disputes. Drawing on a background in economics, he brings a quantitative, business-focused approach to litigation.

Andrew has won cases at every stage – winning motions to dismiss, defeating class certification, obtaining summary judgment and prevailing at trial. He has worked on cases involving alleged securities fraud, commodities manipulation, price-fixing, breach of contract, veil-piercing and patent infringement. Andrew also represents companies and accounting firms in sensitive regulatory matters, including proceedings involving the US Securities and Exchange Commission (SEC), the US Commodity Futures Trading Commission, the US Department of Justice and the Public Company Accounting Oversight Board (PCAOB).

Before law school, Andrew was an economic analyst at the New York State Office of the Attorney General, where he developed models to assess the impact of alleged unlawful conduct and proposed mergers for the Investor Protection Bureau, Antitrust Bureau and Health Care Bureau.

Andrew maintains an active pro bono practice and has received several awards for that work.

Andrew’s recent representative experience:

• Defended a major technology company in a federal securities fraud class action and related derivative actions concerning allegedly false public disclosures
• Defended a Big Four accounting firm in securities class action that was successfully resolved after an appellate court granted Rule 23(f) review of the district court’s class certification decision*
• Represented a global bank in LIBOR and EURIBOR class actions alleging price-fixing and manipulation, including defeating class certification through successful challenges to plaintiffs’ econometric models and helping secure summary judgment in the LIBOR multidistrict litigation*
• Secured dismissal at the motion-to-dismiss stage of an antitrust class action concerning European government bonds*
• Secured a directed verdict in favor of a pharmaceutical-development private equity firm*
• Secured a dismissal of a $210 million royalty refund claim for a pharmaceutical company*
• Obtained a jury verdict for a plaintiff in patent litigation against a major technology company*
• Obtained a summary judgment for a major technology company that was a defendant in a patent dispute*
• Handled coordinated securities and derivative litigation and an SEC investigation related to a fintech company*
• Represented accounting firms in SEC and PCAOB matters involving audit quality and auditor independence

*Representation handled before joining Cooley